Last reviewed · How we verify
Linerixibat tablet
At a glance
| Generic name | Linerixibat tablet |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN) (PHASE3)
- Food Effect Study of Linerixibat Tablets in Healthy Adult Participants (PHASE1)
- Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis (PHASE2)
- Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects (PHASE1)
- Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linerixibat tablet CI brief — competitive landscape report
- Linerixibat tablet updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI